BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 33311949)

  • 1. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
    Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
    World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.
    Tantanavipas S; Vallibhakara O; Sobhonslidsuk A; Phongkitkarun S; Vallibhakara SA; Promson K; Sophonsritsuk A
    Biomed Res Int; 2019; 2019():9047324. PubMed ID: 31467918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
    Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
    Wang D; Nan N; Bing H; He B
    Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.
    Salva-Pastor N; López-Sánchez GN; Chávez-Tapia NC; Audifred-Salomón JR; Niebla-Cárdenas D; Topete-Estrada R; Pereznuñez-Zamora H; Vidaltamayo-Ramírez R; Báez-Arellano ME; Uribe M; Nuño-Lámbarri N
    Ann Hepatol; 2020; 19(3):251-257. PubMed ID: 32111488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
    Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome.
    Chakraborty S; Ganie MA; Masoodi I; Jana M; ; Gupta N; Sofi NY
    Indian J Med Res; 2020 Apr; 151(4):333-341. PubMed ID: 32461397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
    Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
    Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
    Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
    Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
    Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
    PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
    Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
    J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
    Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
    Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
    Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
    Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
    Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome.
    Patel-Sanchez N; Perito E; Tsai P; Raymond-Flesch M; Lodish M; Sarkar M
    J Pediatr Endocrinol Metab; 2023 May; 36(5):441-446. PubMed ID: 37060356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
    Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
    J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.